Belinda M Dcosta

TL;DR: Findings suggest that antibodies elicited by primary infection and by the BNT162b2 mRNA vaccine are likely to maintain protective efficacy against SARS-CoV-2 variants but that the partial resistance of virus with the B.1.1-1.351 spike protein could render some individuals less well protected, supporting a rationale for the development of modified vaccines containing E484K.

TL;DR: In this paper, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared, showing that BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants.

TL;DR: An improved soluble ACE2 is reported, termed a “microbody” in which the ACE2 ectodomain is fused to Fc domain 3 of the immunoglobulin heavy chain and it inhibits entry of β coronaviruses and virus with the variant D614G spike.

TL;DR: In this paper, the authors tested monoclonal antibodies REGN10933 and REGN10987 that are used in combination, for their ability to neutralize SARS-CoV-2 variants B.1.7, mink cluster 5 and COH.

TL;DR: In this article, the authors show that convalescent-phase sera neutralize pseudotyped viruses with the B.1.7, B.351 and B. 1.248 with only a 3fold decrease in titer, an effect attributable to E484K.